Cure My Disease

Don't miss your cure!

 Log in / Sign up

Triple-Drug cocktail targets Hard-to-Treat brain cancer

NCT ID NCT04421560

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a combination of three drugs—pembrolizumab, ibrutinib, and rituximab—in people whose primary central nervous system lymphoma has returned or not responded to treatment. The goal is to see if the combination can stop the cancer from growing for at least 6 months. About 37 participants will receive the drugs, and researchers will monitor side effects and how well the cancer responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pembrolizumab, Ibrutinib, and Rituximab
What this could lead to
If successful, this combination could offer a new treatment option for patients with hard-to-treat brain lymphoma that has come back or not responded to prior therapy.
What could go wrong
This is an early-phase trial with only 37 participants, so results may not apply broadly. The drug combination may cause significant side effects, and it is not yet known if it will improve long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm primary central nervous system lymphoma Recurrence refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA RECURRENT CANCER REFRACTORY CANCER RELAPSED CANCER

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Columbia University Medical Center

    WITHDRAWN

    New York, New York, 10032, United States

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.